Johnson Matthey share price is down 25%! Time to buy?

Since the start of the year, Johnson Matthey’s share price has tumbled by roughly 25%. Is now a good time to invest in the company?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With its share price falling by 25% in the year to date, Johnson Matthey (LSE: JMAT) might now be on the radar of value investors. 

I think it is worth investigating whether the stock is currently trading at bargain buy levels or if the shares are a dangerous value trap.

Johnson Matthey’s falling share price

The FTSE 100 index has been rocked by the Covid-19 pandemic. In the year to date, the index has fallen by 16%. Why has Johnson Matthey’s share price dropped by so much more than the index? 

Johnson Matthey is a global leader in sustainable technologies, with a history that dates back over 200 years. 

The company dominates the market. For example, one in every three new cars is fitted with an emission control catalyst produced by Johnson Matthey. The company’s catalysts stop approximately 20m tonnes of pollutants every year. Its products are also used in pharmaceuticals, chemicals, batteries, and medical products.

Despite its strong position in the market, the prediction is that the full-year group operating performance will not meet the expectations of the market. CEO Robert MacLeod stated that this is due to a “deterioration in some of our end markets”. However, he also noted that Johnson Matthey was “on track to deliver results in line with market expectations this year, prior to developments with Covid-19”. 

Falling car sales following the coronavirus lockdown will affect Johnson Matthey’s revenue. Numerous automotive manufacturers paused productions, which lead to the business closing some of its Clean Air plants.

However, it is not all bad news for JMAT, with parts of the business more resilient to the economic fallout of coronavirus. These sections include its pharmaceutical, health, and agricultural operations. Although services for these sectors are continuing, there have been some delays in shipments. 

Bargain buy or value trap?

As tempting as a major slump in share price looks, investors should ensure they are not falling into a value trap.

Johnson Matthey firmly falls into the FTSE 100 bargain buy category, I believe. The shares are trading at a price-to-earnings ratio of just over 9. As fellow-Fool Cliff D’Arcy points out, the Johnson Matthey share price is trading at a nine-year low. To me, there is now a rare opportunity to buy the stock at a discount.

I think the market has undervalued Johnson Matthey’s share price. The company has a strong balance sheet, with £250m of unrestricted cash and a £1bn revolving credit facility in place until March 2025. 

Johnson Matthey also benefits from a diverse range of revenue streams. Hopefully, this will enable the company to ride out other macro-economic blips and might offer a prudent investor a wide margin of safety.

For a long-term FTSE 100 investor looking to maximise returns, I believe Johnson Matthey’s share price is a great bargain buy.

T Sligo has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

British coins and bank notes scattered on a surface
Investing Articles

£100 invested in a Stocks and Shares ISA today could be worth…

A Stocks and Shares ISA is a proven way of building wealth. But how much could a smaller stake of…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

April opportunities: 2 heavily-discounted stocks to consider buying

Are under-the-radar growth stocks the best place to look for potential stocks to buy as investors look for certainty in…

Read more »

Workers at Whiting refinery, US
Investing Articles

Why the BP share price *finally* surged 24.5% in March

Long-term owners of BP stock have had a frustrating few years, but is the share price rising 24.5% in March…

Read more »

Night Takeoff Of The American Space Shuttle
Investing For Beginners

Why April could be the start of a stock market recovery

Jon Smith lays out the blueprint of different catalysts that could lead to April being a solid month for a…

Read more »

Typical street lined with terraced houses and parked cars
Investing Articles

This FTSE 100 stock has fallen 50% and directors are loading up on shares

This FTSE 100 name has crashed spectacularly and company directors are snapping up shares. Clearly, these insiders expect it to…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

I like Rolls-Royce shares but not the price tag. Here are 2 cheaper alternatives

Rolls-Royce is an incredible company but its shares are richly valued. So are there alternative stocks offering exposure to its…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

Should I buy Lloyds shares before the ISA deadline?

Dr James Fox takes a closer look at Lloyds' shares with the Stocks and Shares ISA deadline fast approaching. The…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

£10,000 invested in Nvidia stock 1 year ago is now worth…

Nvidia stock isn't just important for its shareholders. It's the bellwether for the technology sector and AI. Dr James Fox…

Read more »